Compare AFLAC Incorporated (AFL) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Church & Dwight Co., Inc. — how do they compare? AFLAC Incorporated trades at $121.38 (market cap $61.84B), while Church & Dwight Co., Inc. trades at $96.07 (market cap $23.45B). The key difference: AFLAC Incorporated is far larger — about 2.6× Church & Dwight Co., Inc.'s market cap, and AFLAC Incorporated pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AFL | CHD | |
|---|---|---|
Market Cap | $61.84B | $23.45B |
Sector | Financials | Consumer Staples |
52-Week High | $121.49 | $105.26 |
52-Week Low | $98.09 | $81.60 |
Enterprise Value | $70.50B | $25.15B |
Dividend Yield | 2.01% | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
Church & Dwight (CHD) trades at $98.95, up 0.35% with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q1 2026 adjusted EPS of $0.95 beating the $0.93 estimate (Zacks Investment Research, 2026-05-01). Recent acquisition of Miss Mouth's brand for $325 million strengthens its fabric care portfolio. Valuation metrics show a P/E of 32.43 and ROE of 16.78%, indicating premium pricing but strong profitability.
Outlook remains positive with 53% analyst buy ratings and a $100.50 consensus target, though net cash flow turned negative in 2025. Risks include cost pressures impacting margins, as seen in Q1 profit slippage (WSJ, 2026-05-01), and high debt levels. The stock offers growth potential through organic sales expansion and strategic acquisitions, but investors should monitor margin sustainability and competitive dynamics in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
